RT Journal Article
SR Electronic
T1 Typically asymptomatic but with robust antibody formation: Children’s unique humoral immune response to SARS-CoV-2
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.07.20.21260863
DO 10.1101/2021.07.20.21260863
A1 Renk, Hanna
A1 Dulovic, Alex
A1 Becker, Matthias
A1 Fabricius, Dorit
A1 Zernickel, Maria
A1 Junker, Daniel
A1 Seidel, Alina
A1 Groß, Rüdiger
A1 Hilger, Alexander
A1 Bode, Sebastian
A1 Fritsch, Linus
A1 Frieh, Pauline
A1 Haddad, Anneke
A1 Görne, Tessa
A1 Remppis, Jonathan
A1 Ganzemueller, Tina
A1 Dietz, Andrea
A1 Huzly, Daniela
A1 Hengel, Hartmut
A1 Kaier, Klaus
A1 Weber, Susanne
A1 Jacobsen, Eva-Maria
A1 Kaiser, Philipp D.
A1 Traenkle, Bjoern
A1 Rothbauer, Ulrich
A1 Stich, Maximilian
A1 Tönshoff, Burkhard
A1 Hoffmann, Georg F.
A1 Müller, Barbara
A1 Ludwig, Carolin
A1 Jahrsdörfer, Bernd
A1 Schrezenmeier, Hubert
A1 Peter, Andreas
A1 Hörber, Sebastian
A1 Iftner, Thomas
A1 Münch, Jan
A1 Stamminger, Thomas
A1 Groß, Hans-Jürgen
A1 Wolkewitz, Martin
A1 Engel, Corinna
A1 Rizzi, Marta
A1 Henneke, Philipp
A1 Franz, Axel R.
A1 Debatin, Klaus-Michael
A1 Schneiderhan-Marra, Nicole
A1 Janda, Ales
A1 Elling, Roland
YR 2021
UL http://medrxiv.org/content/early/2021/07/22/2021.07.20.21260863.abstract
AB Background Long-term persistence of antibodies against SARS-CoV-2, particularly the SARS-CoV-2 Spike Trimer, determines individual protection against infection and potentially viral spread. The quality of children’s natural humoral immune response following SARS-CoV-2 infection is yet incompletely understood but crucial to guide pediatric SARS-CoV-2 vaccination programs.Methods In this prospective observational multi-center cohort study, we followed 328 households, consisting of 548 children and 717 adults, with at least one member with a previous laboratory-confirmed SARS-CoV-2 infection. The serological response was assessed at 3-4 months and 11-12 months after infection using a bead-based multiplex immunoassay for 23 human coronavirus antigens including SARS-CoV-2 and its Variants of Concern (VOC) and endemic human coronaviruses (HCoVs), and additionally by three commercial SARS-CoV-2 antibody assays.Results Overall, 33.76% of SARS-CoV-2 exposed children and 57.88% adults were seropositive. Children were five times more likely to have seroconverted without symptoms compared to adults. Despite the frequently asymptomatic course of infection, children had higher specific antibody levels, and their antibodies persisted longer than in adults (96.22% versus 82.89% still seropositive 11-12 months post infection). Of note, symptomatic and asymptomatic infections induced similar humoral responses in all age groups. In symptomatic children, only dysgeusia was found as diagnostic indicator of COVID-19. SARS-CoV-2 infections occurred independent of HCoV serostatus. Antibody binding responses to VOCs were similar in children and adults, with reduced binding for the Beta variant in both groups.Conclusions The long-term humoral immune response to SARS-CoV-2 infection in children is robust and may provide long-term protection even after asymptomatic infection.(Study ID at German Clinical Trials Register: 00021521)Competing Interest StatementNSM was a speaker at Luminex user meetings in the past. The Natural and Medical Sciences Institute at the University of Tuebingen is involved in applied research projects as a fee for services with Luminex. The other authors report no competing interests.Clinical TrialGerman Clinical Trials Register: 00021521Funding StatementThe COVID-19 BaWue study was funded by the Ministry of Science, Research and Arts, Baden-Wuerttemberg, Germany (COVID-19 research framework).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved by the independent ethics committees of the Medical Faculty Heidelberg (S-294/2020), Medical Faculty Tuebingen (293/2020BO2), University of Ulm 107 (152/20) and University of Freiburg (256/20_201553).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData from this study are available upon request.